This Interactive Decision Support Tool provides HBV management recommendations from US, European, or Asian Pacific guidelines based on the specific patient characteristics you enter. (See “About This Tool” in the Table of Contents for more information.)
After viewing the recommendations from the guideline of your choice, you will have an opportunity to tell us whether they either confirmed or changed your management choices and leave any comments about this tool.
The current tool was created in January 2019 and reflects the guidelines at that time.
Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for monitoring or treating individuals with chronic HBV infection. The information provided is based on the AASLD, EASL, and APASL guideline recommendations and expert guidance of Kosh Agarwal, BMed, Sci(Hons), MD, FRCP; Paul Y. Kwo, MD; and Grace LH Wong, MBChB(Hons), MD, FRCP(Lond, Edin), FHKCP, FHKAM(Medicine).
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
© 2019 Clinical Care Options, LLC. All rights reserved.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Professor
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong
Scientific Director
Editorial Contributor
Senior Clinical Editor
Director, Scientific Services
Executive Vice President
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for monitoring or treating individuals with chronic HBV infection. The information provided is based on the AASLD, EASL, and APASL guideline recommendations and expert guidance of Kosh Agarwal, BMed, Sci(Hons), MD, FRCP; Paul Y. Kwo, MD; and Grace LH Wong, MBChB(Hons), MD, FRCP(Lond, Edin), FHKCP, FHKAM(Medicine).
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
This program is intended for physicians and other healthcare providers who provide care for patients with HBV infection.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 21, 2019, through March 20, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.
You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Download this PDF guide outlining key information on HCC risk assessment, screening, and surveillance in the setting of Hepatitis B infection
Expert CCO commentary on how to incorporate noninvasive methods to assess fibrosis into management of patients with HBV infection
Watch this brief presentation by Dr. Paul Kwo on interpreting serology, HBV DNA, and fibrosis assessments to determine HBV treatment candidacy.
Download free expert-authored slides reviewing AASLD guidance on HBV management pretreatment evaluation to determine treatment candidacy
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.